tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2023 Dec 11.
doi: 10.1080/14760584.2023.2293237. Online ahead of print. A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons
Myron J Levin[SUP] 1 [/SUP], Victoria Divino[SUP] 2 [/SUP], Maarten J Postma[SUP] 3 4 5 [/SUP], Stephen I Pelton[SUP] 6 7 [/SUP], Zifan Zhou[SUP] 2 [/SUP], Mitch DeKoven[SUP] 2 [/SUP], Joaquin Mould-Quevedo[SUP] 8 [/SUP]
Affiliations
Background: Clinical evidence supports use of enhanced influenza vaccines in older adults. Few economic outcome studies have compared adjuvanted trivalent inactivated (aIIV3) and standard egg-derived quadrivalent inactivated influenza vaccines (IIV4e).
Research design and methods: A retrospective cohort study was conducted leveraging deidentified US hospital data linked to claims data during the 2018-19 and 2019-20 influenza seasons. Relative vaccine effectiveness (rVE) was compared in adults aged ≥65 years receiving aIIV3 or IIV4e using inverse probability of treatment weighting (IPTW) and Poisson regression. An economic assessment quantified potential real-world cost savings.
Results: The study included 715,807 aIIV3 and 320,991 IIV4e recipients in the 2018-19 and 844,169 aIIV3 and 306,270 IIV4e recipients in the 2019-20 influenza seasons. aIIV3 was significantly more effective than IIV4e in preventing cardiorespiratory disease (2018-19 rVE = 6.2%; and 2019-20 rVE = 6.0%) and respiratory disease (2018-19 rVE = 8.9%; and 2019-20 rVE = 10.1%). During the 2018-19 influenza season cardiorespiratory hospitalization cost savings for the aIIV3 population was $392 M, and $221 M for the 2019-20 season. Respiratory hospitalization cost savings for the aIIV3 population was $145 M and $97 M, respectively.
Conclusions: Our findings suggest that aIIV3 provides clinical and economic advantages versus IIV4e in the elderly.
Keywords: Adjuvanted; Elderly; Relative vaccine effectiveness; aIIV3; economic assessment; influenza vaccine.
. 2023 Dec 11.
doi: 10.1080/14760584.2023.2293237. Online ahead of print. A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons
Myron J Levin[SUP] 1 [/SUP], Victoria Divino[SUP] 2 [/SUP], Maarten J Postma[SUP] 3 4 5 [/SUP], Stephen I Pelton[SUP] 6 7 [/SUP], Zifan Zhou[SUP] 2 [/SUP], Mitch DeKoven[SUP] 2 [/SUP], Joaquin Mould-Quevedo[SUP] 8 [/SUP]
Affiliations
- PMID: 38073493
- DOI: 10.1080/14760584.2023.2293237
Background: Clinical evidence supports use of enhanced influenza vaccines in older adults. Few economic outcome studies have compared adjuvanted trivalent inactivated (aIIV3) and standard egg-derived quadrivalent inactivated influenza vaccines (IIV4e).
Research design and methods: A retrospective cohort study was conducted leveraging deidentified US hospital data linked to claims data during the 2018-19 and 2019-20 influenza seasons. Relative vaccine effectiveness (rVE) was compared in adults aged ≥65 years receiving aIIV3 or IIV4e using inverse probability of treatment weighting (IPTW) and Poisson regression. An economic assessment quantified potential real-world cost savings.
Results: The study included 715,807 aIIV3 and 320,991 IIV4e recipients in the 2018-19 and 844,169 aIIV3 and 306,270 IIV4e recipients in the 2019-20 influenza seasons. aIIV3 was significantly more effective than IIV4e in preventing cardiorespiratory disease (2018-19 rVE = 6.2%; and 2019-20 rVE = 6.0%) and respiratory disease (2018-19 rVE = 8.9%; and 2019-20 rVE = 10.1%). During the 2018-19 influenza season cardiorespiratory hospitalization cost savings for the aIIV3 population was $392 M, and $221 M for the 2019-20 season. Respiratory hospitalization cost savings for the aIIV3 population was $145 M and $97 M, respectively.
Conclusions: Our findings suggest that aIIV3 provides clinical and economic advantages versus IIV4e in the elderly.
Keywords: Adjuvanted; Elderly; Relative vaccine effectiveness; aIIV3; economic assessment; influenza vaccine.